Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims
Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims
Xuan Wang
1
, PhD ;
Anna M Plantinga
2
, PhD ;
Xin Xiong
3
, MSc ;
Sara J Cromer
4
, MD ;
Clara-Lea Bonzel
5
, MSc ;
Vidul Panickan
5
, MSc ;
Rui Duan
3
, PhD ;
Jue Hou
6
, PhD ;
Tianxi Cai
3
, PhD
1
Department of Population Health Sciences, University of Utah, Salt Lake City, UT, United States
2
Department of Mathematics and Statistics, Williams College, Williamstown, MA, United States
3
Department of Biostatistics, Harvard University, Boston, MA, United States
4
Department of Medicine, Massachusetts General Hospital, Boston, MA, United States
5
Department of Biomedical Informatics, Harvard University, Boston, MA, United States
6
Department of Biostatistics, University of Minnesota, Minneapolis, MN, United States